• English
    • français
    • Deutsch
    • español
    • português (Brasil)
    • Bahasa Indonesia
    • русский
    • العربية
    • 中文
  • English 
    • English
    • français
    • Deutsch
    • español
    • português (Brasil)
    • Bahasa Indonesia
    • русский
    • العربية
    • 中文
  • Login
View Item 
  •   Home
  • OAI Data Pool
  • OAI Harvested Content
  • View Item
  •   Home
  • OAI Data Pool
  • OAI Harvested Content
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of the LibraryCommunitiesPublication DateTitlesSubjectsAuthorsThis CollectionPublication DateTitlesSubjectsAuthorsProfilesView

My Account

LoginRegister

The Library

AboutNew SubmissionSubmission GuideSearch GuideRepository PolicyContact

Development and use of a Monte Carlo-Markov cycle tree model for coronary heart disease incidence-mortality and health service usage with explicit recognition of coronary artery revascularization procedures (CARPs) /

  • CSV
  • RefMan
  • EndNote
  • BibTex
  • RefWorks
Author(s)
Mannan, Haider Rashid
University of Western Australia.School of Population Health
Keywords
Coronary heart disease
Coronary heart disease
Coronary heart disease
Myocardial revascularization
Monte Carlo method
Markov processes
Medicine

Full record
Show full item record
URI
http://hdl.handle.net/20.500.12424/1045952
Online Access
http://repository.uwa.edu.au:80/R/?func=dbin-jump-full&object_id=9938&local_base=GEN01-INS01
Abstract
[Truncated abstract] The main objective of this study was to develop and validate a demographic/epidemiologic Markov model for population modelling/forecasting of CARPs as well as CHD deaths and incidence in Western Australia using population, linked hospital morbidity and mortality data for WA over the period 1980 to 2000. A key feature of the model was the ability to count events as individuals moved from one state to another and an important aspect of model development and implementation was the method for estimation of model transition probabilities from available population data. The model was validated through comparison of model predictions with actual event numbers and through demonstration of its use in producing forecasts under standard extrapolation methods for transition probabilities as well as improving the forecasts by taking into account various possible changes to the management of CHD via surgical treatment changes. The final major objective was to demonstrate the use of model for performing sensitivity analysis of some scenarios. In particular, to explore the possible impact on future numbers of CARPs due to improvements in surgical procedures, particularly the introduction of drug eluting stents, and to explore the possible impact of change in trend of CHD incidence as might be caused by the obesity epidemic. ... When the effectiveness of PCI due to introduction of DES was increased by reducing Pr(CABG given PCI) and Pr(a repeat PCI), there was a small decline in the requirements for PCIs and the effect seemed to have a lag. Finally, in addition to these changes when other changes were incorporated which captured that a PCI was used more than a CABG due to a change in health policy after the introduction of DES, there was a small increase in the requirements for PCIs with a lag in the effect. Four incidence scenarios were developed for assessing the effect of change in secular trends of CHD incidence as might be caused by the obesity epidemic in such a way that they gradually represented an increasing effect of obesity epidemic (assuming that other risk factors changed favourably) on CHD incidence. The strategy adopted for developing the scenarios was that based on past trends the most dominant component of CHD incidence was first gradually altered and finally the remaining components were altered. iv The results showed that if the most dominant component of CHD incidence, eg, Pr(CHD - no history of CHD) levelled off and the trends in all other transition probabilities continued into future, then the projected numbers of CABGs and PCIs for 2001-2005 were insensitive to these changes. Even increasing this probability by as much as 20 percent did not alter the results much. These results implied that the short-term effect on projected numbers of CARPs caused by an increase in the most dominant component of CHD incidence, possibly due to an 'obesity epidemic' is small. In the final incidence scenario, two of the remaining CHD incidence components-Pr(CABG - no history of CHD) and Pr(CHD death - no CHD and no history of CHD) were projected to level off over 2001-2005 because these probabilities were declining over the baseline period of 1998-2000. The projected numbers of CABGs were more sensitive (compared to the previous scenarios) to these changes but PCIs were not.
Thesis (Ph.D.)--University of Western Australia, 2008
[Truncated abstract] The main objective of this study was to develop and validate a demographic/epidemiologic Markov model for population modelling/forecasting of CARPs as well as CHD deaths and incidence in Western Australia using population, linked hospital morbidity and mortality data for WA over the period 1980 to 2000. A key feature of the model was the ability to count events as individuals moved from one state to another and an important aspect of model development and implementation was the method for estimation of model transition probabilities from available population data. The model was validated through comparison of model predictions with actual event numbers and through demonstration of its use in producing forecasts under standard extrapolation methods for transition probabilities as well as improving the forecasts by taking into account various possible changes to the management of CHD via surgical treatment changes. The final major objective was to demonstrate the use of model for performing sensitivity analysis of some scenarios. In particular, to explore the possible impact on future numbers of CARPs due to improvements in surgical procedures, particularly the introduction of drug eluting stents, and to explore the possible impact of change in trend of CHD incidence as might be caused by the obesity epidemic. ... When the effectiveness of PCI due to introduction of DES was increased by reducing Pr(CABG given PCI) and Pr(a repeat PCI), there was a small decline in the requirements for PCIs and the effect seemed to have a lag. Finally, in addition to these changes when other changes were incorporated which captured that a PCI was used more than a CABG due to a change in health policy after the introduction of DES, there was a small increase in the requirements for PCIs with a lag in the effect. Four incidence scenarios were developed for assessing the effect of change in secular trends of CHD incidence as might be caused by the obesity epidemic in such a way that they gradually represented an increasing effect of obesity epidemic (assuming that other risk factors changed favourably) on CHD incidence. The strategy adopted for developing the scenarios was that based on past trends the most dominant component of CHD incidence was first gradually altered and finally the remaining components were altered. iv The results showed that if the most dominant component of CHD incidence, eg, Pr(CHD - no history of CHD) levelled off and the trends in all other transition probabilities continued into future, then the projected numbers of CABGs and PCIs for 2001-2005 were insensitive to these changes. Even increasing this probability by as much as 20 percent did not alter the results much. These results implied that the short-term effect on projected numbers of CARPs caused by an increase in the most dominant component of CHD incidence, possibly due to an 'obesity epidemic' is small. In the final incidence scenario, two of the remaining CHD incidence components-Pr(CABG - no history of CHD) and Pr(CHD death - no CHD and no history of CHD) were projected to level off over 2001-2005 because these probabilities were declining over the baseline period of 1998-2000. The projected numbers of CABGs were more sensitive (compared to the previous scenarios) to these changes but PCIs were not.
Date
2007
Type
Thesis
Identifier
oai:repository.uwa.edu.au:9938
http://repository.uwa.edu.au:80/R/?func=dbin-jump-full&object_id=9938&local_base=GEN01-INS01
Collections
OAI Harvested Content

entitlement

 

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    The pre-test risk stratified cost-effectiveness of 64-slice computed tomography coronary angiography in the detection of significant obstructive coronary artery disease in patients otherwise referred to invasive coronary angiography

    Kreisz, F.; Merlin, T.; Moss, J.; Atherton, J.; Hiller, J.; Gericke, C. (Blackwell Publishing Asia, 2009)
    Background This study evaluates the cost-effectiveness of 64-slice computed tomography coronary angiography (CTCA) as an alternative to invasive diagnostic coronary angiography (CA) in an elective outpatient setting for patients otherwise referred to invasive diagnostic coronary angiography. Methods Taking the perspective of the Australian health system we used a decision analytic model to integrate data on test accuracy along with complication rates, health state preference weights and health care costs. The analysis is pre-test risk stratified based on Bayes’ theorem of conditional probability. Incremental cost-effectiveness ratios (ICER) are the study endpoints expressed as incremental costs per quality adjusted life year (QALY) gained. Results The results indicate that CTCA is a cost-saving strategy offering a higher health related quality of life up to approximately 65% pre-test risk of coronary artery disease (CAD). Above that threshold the model predicts a cost-utility trade-off with every gain in health related quality of life through the use of CTCA as a rule-out test being associated with additional costs when compared to invasive diagnostic CA. Conclusion This health economic analysis predicts computed tomography coronary angiography to be a cost-effective rule-out strategy in symptomatic patients at low to intermediate risk of significant obstructive coronary artery disease otherwise referred to invasive diagnostic CA.
  • Thumbnail

    Cardiac MDCT, beyond coronary angiography : support to learn about extra coronary anomalies on cardiac MDCT except the coronary anomalies.

    Université de Picardie; TEXIER, Agnès; RENARD, Cédric (2010)
    L imagerie cardiaque a beaucoup évolué ces dernières années. Bien que l échographie cardiaque demeure l examen de première intention pour l étude de la fonction et de la morphologie cardiaque, d autres techniques telles que l imagerie par résonance magnétique (IRM) et le scanner sont devenues utiles voire indispensables au diagnostic et à la décision thérapeutique. Le scanner cardiaque s inscrit à la fois comme une technique complémentaire et une alternative à l échographie cardiaque dans certaines pathologies. Bien que moins performant que l IRM en terme de caractérisation tissulaire et de résolution temporelle et parfois d utilisation limitée en raison de son caractère irradiant, le scanner présente certains avantages, notamment sa disponibilité, sa très bonne résolution spatiale et le caractère volumique de son exploration. Ces caractéristiques en font l examen de choix pour l étude non invasive des artères coronaires. Par contre, il reste encore sous-exploité pour l étude des pathologies touchant le myocarde, le péricarde et les cavités cardiaques, souvent mal connues des radiologues. Ce CD-Rom a pour objectif de fournir une base de données et un enseignement didactique des anomalies cardiaques extra-coronaires que l on peut retrouver lors d une exploration cardiaque ou thoracique par scanner multi-détecteur. Cet outil a pour ambition de familiariser les radiologues et les cardiologues à la lecture du scanner cardiaque dans sa globalité afin de ne pas limiter son analyse à celle des artères coronaires.
  • Thumbnail

    Assessment of coronary flow reserve by Doppler flow wIre in patients with acute coronary syndrome undergoing percutaneous coronary intervention: differences between the LoAding dose of Ticagrelor versus prasugrEl (DILATE): study protocol for a randomized controlled trial

    Marianna Cicenia; Andrea Ceccacci; Simone Calcagno; Viviana Maestrini; Nicolò Salvi; Alessandra Cinque; Rocco E Stio; Maurizio Pulcini; Gennaro Sardella; Massimo Mancone; et al. (Wolters Kluwer Medknow Publications, 2016-01-01)
    Background: Percutaneous coronary intervention (PCI) is the main treatment in patients with acute coronary syndromes (ACS). Current guidelines recommend the administration of a loading dose of clopidogrel, ticagrelor or prasugrel during the procedure. Ticagrelor and prasugrel have proven to overcome some limitation related to clopidrogrel administration as of pharmacological resistance. P2Y12 antagonists increase adenosine concentration by inhibiting red blood cells reuptake and induces adenosine triphosphate release from human red blood cells, which is further degraded to adenosine. Ticagrelor has been demonstrated to increase the coronary blood flow velocity more than prasugrel, as assessed by transthoracic Doppler echocardiography after incremental doses of adenosine administration. Currently, no data are available on comparison between prasugrel and clopidrogrel in term of vasodilation effect evaluated invasively. Methods/Design: This prospective, single-center, investigator-initiated, randomized controlled trial will compare the adenosine induced coronary dilatation after the treatment with ticagrelor (180 mg) versus prasugrel (60 mg) in patients with ACS undergoing PCI. A total of 90 patients, aged ≥ 18 and ≤ 75 years, admitted with ACS, treated by PCI with stent implantation and with a second intermediate non-culprit lesion will be included and randomized 1:1 to prasugrel (60 mg) or ticagrelor (180 mg). Coronary flow reserve (CFR), the study endpoint, will be recorded before the stent implantation on the intermediate lesion, then immediately after the stent implantation and during the adenosine intravenous administration at incremental doses of 50, 80, 110 and 140 μg/kg/min with 2-minute interval between infusions. Discussion: Our clinical trial, for the first time, will evaluate the supposed adenosine induced effect of the ticagrelor in terms of coronary vasodilatation calculated by CFR. Currently, CFR represents the gold standard to assess the ability of the myocardium to increase blood flow in response to maximal exercise. Furthermore, this trial will be the first to compare the effects of ticagrelor versus prasugrel on patients ACS. This trial will allow to better understand the physiological pathway of coronary vasodilatiation induced by ticagrelor versus prasugrel using invasive methods. Trial registration: ClinicalTrials.gov identifier: NCT02032303; registered on December 18, 2013. Ethics: The study was approved by the Ethics Committee of Policlinico Umberto I Rome Hospital (approval No. 2322/15) and will be performed in accordance with the ethical standards of the responsible committee on human experimentation and the Declaration of Helsinki. Informed consent: A signed informed consent will be given by each patient with ACS before undergoing angiography.
DSpace software (copyright © 2002 - 2021)  DuraSpace
Quick Guide | Contact Us
Open Repository is a service operated by 
Atmire NV
 

Export search results

The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.